Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study

作者：Amit Bar-Or, Michal Dufek, Hrvoje Budinčević, Jelena S. Drulovic, Mario Habek, Le Hanh Hua, Martin S. Weber, Piia Thomas, Julie A. Napieralski, Maresa Caunt Mitzner, John N. Ratchford, David Clayton, Christopher T. Harp, Denison Kuruvilla, Qi Qi, Ying-Fang Chen, Yan Xu, Alexandra Goodyear, Jiwon Oh, Sanja Grgic, Hrvoje Budincevic, Mario Habek, Spomenka Kidemet Piskac, Vladimira Vuletic, Radek Ampapa, Michal Dufek, Jana Lizrova Preiningerova, Zbyšek Pavelek, Jelena Drulovic, Smiljana Kostic, Svetlana Miletic Drakulic, Dusica Smiljanic-Miljkovic, Slobodan Vojinovic, Viera Hančinová, Jack Florin, Le Hua, Kenneth Sharlin · 发表于：The Lancet Neurology · 年份：2025 · DOI：10.1016/s1474-4422(25)00174-7 · 被引用次数：31 · 研究领域：Multiple Sclerosis Research Studies、PI3K/AKT/mTOR signaling in cancer、Chronic Lymphocytic Leukemia Research